Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another Fine Mess For AZ As ‘Outdated’ Vaccine Data Queried

Newer Data Gives Lower Efficacy Score

Executive Summary

A new “unforced error” from AstraZeneca in reporting clinical data is keeping its COVID-19 vaccine in the headlines for the wrong reasons.

You may also be interested in...



After Vaccine Results Row, AZ Recalculates And Looks To Move On

AstraZeneca will want to move on from the incident, but is certain to face extra scrutiny at the US FDA.

AZ COVID-19 Vaccine Scores 79% In Pivotal US Trial – Any Hope For A Fresh Start?

The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.

Beam Therapeutics’ Base-Edited CAR-T Placed On Hold

Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel